The milestone article will trace the controversial discovery of prostate-specific antigen (PSA) and the subsequent purification, characterization, and clinical use of PSA as a biomarker blood test for prostate cancer.
The acquisition brings together two leaders in scientific software to provide end-to-end support from molecular design and analytical characterization to manufacturing quality control.
Paired with OGT’s Interpret platform, the solution allows labs to visualise MRD dynamics over time and streamline workflows while maintaining accuracy and reproducibility.